WST FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 7 Deadline in Securities Class Action – WST

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1]. Group 1: Class Action Details - Investors who bought West common stock between February 16, 2023, and February 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lead plaintiff must file a motion with the court by July 7, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in terms of settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that West Pharmaceutical Services made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5]. - It is claimed that West was experiencing significant destocking in its high-margin products, contrary to its public statements about strong customer demand [5]. - The lawsuit also indicates that operational inefficiencies related to the SmartDose device negatively impacted profit margins, leading to potential restructuring activities [5].